Agilent Companion Diagnostic Expands CE-IVD Mark in Europe to Include Esophageal Cancer

Agilent Companion Diagnostic Expands CE-IVD Mark in Europe to Include Esophageal Cancer

PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify esophageal cancer patients for treatment with KEYTRUDA® (pembrolizumab)

Agilent Technologies Inc. (NYSE: A) today announced that the company’s PD-L1 IHC 22C3 pharmDx assay has expanded its use in Europe. The assay is now CE-IVD marked for use as an aid in identifying esophageal cancer patients for treatment with KEYTRUDA using Combined Positive Score (CPS) ≥ 10.1 In Europe, KEYTRUDA is approved in combination with platinum- and fluoropyrimidine-based chemotherapy for patients with locally advanced unresectable or metastatic esophageal carcinoma or HER2 negative gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ≥ 10].2. Read more